Alzamend Neuro (ALZN) vs Processa Pharmaceuticals (PCSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Processa Pharmaceuticals is the larger company by market cap ($4.4 million vs $3.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALZN | PCSA |
|---|---|---|
| Share price | $0.7758 | $1.56 |
| Market cap | $3.74M | $4.37M |
| 1-day change | -23.94% | -7.69% |
| EPS (TTM) | $-2.30 | $-68.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-8.77M | $-13.56M |
| 52-week high | $2.54 | $8.88 |
| 52-week low | $0.754 | $1.04 |
| Distance from 52-week high | -69.40% | -82.43% |
| Analyst consensus | none | — |
| Avg. price target upside | +3251.38% | — |
| Average volume | 70.27K | 79.50K |
| Shares outstanding | 4.83M | 2.80M |
| Employees | 4 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alzamend Neuro
ALZN stock →Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Processa Pharmaceuticals
PCSA stock →Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
ALZN vs PCSA FAQ
Which is bigger, Alzamend Neuro or Processa Pharmaceuticals?
Processa Pharmaceuticals (PCSA) is larger, with a market capitalization of $4.37M compared with $3.74M for Alzamend Neuro (ALZN).
Are Alzamend Neuro and Processa Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.